当前位置: 首页 >> 检索结果
1. NURSE-Led Care in Patients Undergoing Catheter Ablation for Atrial Fibrillation: The NURSECAT-AF Randomized Trial.
作者: Alba Cano-Valls.;Maria Antonia Martinez Monblan.;Esther Carro-Fernández.;Mireia Niebla.;Rebeca Domingo.;Sara Hevia-Puyo.;Montserrat Venturas-Nieto.;Roger Borras.;José María Tolosana.;Andreu Porta-Sánchez.;Jean-Baptiste Guichard.;Till F Althoff.;Ivo Roca-Luque.;Lluis Mont.;Eduard Guasch.
来源: Circ Arrhythm Electrophysiol. 2026年19卷3期e014149页
Atrial fibrillation (AF) is associated with reduced quality of life and frequent hospitalizations. Integrated nurse-led care (NLC) has proven beneficial in unselected AF patients, but evidence specific to patients undergoing catheter ablation is limited. We aimed to assess the impact of a structured nurse-led intervention in patients undergoing first-time AF ablation.
2. Risk in Women Emerges at Lower Coronary Plaque Burden Than in Men: PROMISE Trial.
作者: Jan M Brendel.;Thomas Mayrhofer.;Júlia Karády.;Márton Kolossváry.;Nóra M Kerkovits.;Isabel L Langenbach.;Matthias Jung.;Michelle D Kelsey.;Marcel C Langenbach.;Neha Pagidipati.;Svati H Shah.;Michael T Lu.;Maros Ferencik.;Pamela S Douglas.;Borek Foldyna.
来源: Circ Cardiovasc Imaging. 2026年19卷3期e019011页
Quantitative coronary plaque measures differ in prognostic value between women and men. It remains unclear whether cardiovascular risk increases proportionally with plaque extent in both sexes. We aimed to compare cardiovascular risk trajectories across quantitative coronary plaque measures in women and men with stable chest pain.
3. Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.
作者: Julian S Haimovich.;Shinwan Kany.;Yuchiao Chang.;Leila H Borowsky.;David D McManus.;Steven J Atlas.;Daniel E Singer.;Steven A Lubitz.;Patrick T Ellinor.;Shaan Khurshid.
来源: Circulation. 2026年153卷6期367-378页
Stressor-associated atrial fibrillation (AF), defined as newly diagnosed AF in the setting of a reversible physiological stressor, is common. However, risk factors, outcomes, and current management practices remain poorly understood.
4. Association Between the 2022 AHA/ACC/HFSA Heart Failure Staging and Cardiovascular and Kidney Outcomes in Patients With Diabetes and Kidney Disease: A Post Hoc Analysis of the SCORED Randomized Controlled Trial.
作者: Ayodele Odutayo.;Deepak L Bhatt.;Vikas S Sridhar.;Michael Szarek.;Christopher P Cannon.;Lawrence A Leiter.;Darren K McGuire.;Julia B Lewis.;Renato D Lopes.;Benjamin M Scirica.;Kausik K Ray.;Michael J Davies.;Phillip Banks.;Manon Girard.;Subodh Verma.;Jacob A Udell.;Bertram Pitt.;Ph Gabriel Steg.;David Z I Cherney.
来源: Circ Heart Fail. 2026年19卷3期e013054页
The 2022 American Heart Association/American College of Cardiology/Heart Failure Society of America heart failure (HF) classification incorporates cardiac biomarkers to identify early risk of HF. The HF stages may also guide the prognosis and management of cardiovascular and kidney-related events.
5. Prognostic Implications of Evolving Universal Definitions of Periprocedural Myocardial Infarction in Patients With Acute Coronary Syndrome.
作者: Sergio Leonardi.;Antonio Landi.;Andrea Zito.;Mattia Branca.;Enrico Frigoli.;Giuseppe Ando'.;Carlo Briguori.;Paolo Calabro.;Andrea Gagnor.;Roberto Garbo.;Dik Heg.;Ugo Limbruno.;Andrea Milzi.;Elmir Omerovic.;Filippo Russo.;Manel Sabaté.;Andrea Santarelli.;Gennaro Sardella.;Paolo Tosi.;Arnoud W J Van't Hof.;Pascal Vranckx.;Marco Valgimigli.
来源: Circulation. 2026年153卷4期230-242页
The universal definition of percutaneous coronary intervention (PCI)-related myocardial infarction (MI) has been substantially updated over the years, including an increase in the biomarker threshold (from 3 to 5 times the upper reference limit) and the introduction of ancillary criteria such as ischemic symptoms and electrocardiographic or angiographic complication. The impact of these changes in patients with acute coronary syndrome (ACS) remains incompletely understood. The objective of this study was to compare prognostic implications of evolving universal definitions of PCI-MI in a large cohort of patients with ACS from the MATRIX trial (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of AngioX).
6. Artificial Intelligence-Enabled Echocardiography as a Surrogate for Multimodality Aortic Stenosis Imaging: Post Hoc Analysis of a Clinical Trial.
作者: Evangelos K Oikonomou.;Neil J Craig.;Gregory Holste.;Sumukh Vasisht Shankar.;Audrey C White.;Menaka Mahendran.;David E Newby.;Marc R Dweck.;Rohan Khera.
来源: Circ Cardiovasc Imaging. 2026年19卷2期e018353页
Accurate aortic stenosis (AS) phenotyping requires multimodality imaging which has limited availability. The digital aortic stenosis severity index (DASSi), an artificial intelligence biomarker of AS-related remodeling on single-view 2-dimensional echocardiography, predicts AS progression independent of Doppler measurements. We sought to evaluate the ability of DASSi to define personalized AS progression profiles and to validate its performance as a scalable alternative to multimodality imaging features of functional, structural, and biological AS severity.
7. Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.
作者: Benjamin W Van Tassell.;Michele Golino.;Justin M Canada.;Roshanak Markley.;Hayley Billingsley.;Marco Giuseppe Del Buono.;Azita Talasaz.;Georgia Thomas.;Juan Guido Chiabrando.;George Wohlford.;Virginia Dickson.;Dinesh Kadariya.;Juan Ignacio Damonte.;Ai-Chen Jane Ho.;Yub Raj Sedhai.;Emily Kontos.;Alessandra Vecchiè.;Joshua D West.;Giuliana Corna.;Horacio Medina de Chazal.;Sebastian Pinel.;Edoardo Bressi.;Andrew Barron.;Megan Dell.;James Mbualungu.;Francesco Moroni.;Jeremy Turlington.;Emily Federmann.;Cory R Trankle.;Salvatore Carbone.;Ross Arena.;Antonio Abbate.
来源: Circ Heart Fail. 2026年19卷3期e013546页
Decompensated heart failure with reduced ejection fraction (HFrEF) is associated with systemic inflammation that predicts unfavorable outcomes. We aimed to determine whether anakinra, an IL-1 (interleukin-1) blocker, favors inflammation resolution (CRP [C-reactive protein]) and improves peak oxygen consumption (VO2) in patients with recently decompensated HFrEF.
8. Physical Exercise or Cognitive Behavioral Therapy for Takotsubo Cardiomyopathy: A Randomized Controlled Trial.
作者: David T Gamble.;James Ross.;Hilal Khan.;Lesley Cheyne.;Amelia Rudd.;Janaki Srivanasan.;Graham Horgan.;Duncan Hogg.;Phyo K Myint.;David E Newby.;Christopher Williams.;Stuart R Gray.;Dana Dawson.
来源: Circ Heart Fail. 2026年19卷3期e013229页
Takotsubo cardiomyopathy is an acute cardiac emergency presenting with severe left ventricular dysfunction. Physical exercise training or cognitive behavioral therapy may enhance myocardial recovery after takotsubo cardiomyopathy.
9. Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.
作者: Sotirios Tsimikas.;Michael Szarek.;Christa M Cobbaert.;Fred Romijn.;J Wouter Jukema.;Deepak L Bhatt.;Vera A Bittner.;Rafael Diaz.;Sergio Fazio.;Genevieve Garon.;Chong Yuan.;Xiao-Min Gong.;Shaun G Goodman.;Harvey D White.;Joseph L Witztum.;P Gabriel Steg.;Gregory G Schwartz.; .
来源: Circulation. 2025年152卷24期1666-1678页
Oxidized phospholipids on apolipoprotein B-100 (OxPL-apoB) reflect pro-inflammatory properties of Lp(a) (lipoprotein(a)). The effect of OxPL-apoB on major adverse cardiovascular events (MACE) in patients with acute coronary syndrome in recent the era is not known.
10. Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial.
作者: Marianna Fontana.;Pablo García-Pavía.;Martha Grogan.;Sanjiv J Shah.;Mads D M Engelmann.;G Kees Hovingh.;Arnt V Kristen.;Michelle Z Lim-Watson.;Brian Malling.;Soumitra Kar.;Manjunatha Revanna.;Nitasha Sarswat.;Kenichi Tsujita.;Kevin M Alexander.;Mathew S Maurer.
来源: Circulation. 2026年153卷4期214-225页
Transthyretin amyloidosis with cardiomyopathy is a progressive disease caused by the deposition of transthyretin (TTR) as amyloid in the myocardium. Current therapies may slow disease progression but do not clear existing deposits. Coramitug is a humanized monoclonal antibody that targets misfolded transthyretin, designed to promote clearance of transthyretin amyloid through antibody-mediated phagocytosis.
11. Dapagliflozin to Reduce Early Recurrence After Catheter Ablation for Atrial Fibrillation: The DARE-AF Randomized Clinical Trial.
作者: Chao Jiang.;Zixu Zhao.;Zejun Yang.;Yiping Wang.;Yang Xu.;Hui Xu.;Hang Guo.;Chi Wang.;Liu He.;Shijun Xia.;Xiangyi Kong.;Wenli Dai.;Junmeng Zhang.;Song Zuo.;Xiaoxia Liu.;Xueyuan Guo.;Nian Liu.;Songnan Li.;Ning Zhou.;Chenxi Jiang.;Ribo Tang.;Caihua Sang.;Paul C Zei.;Deyong Long.;Xin Du.;Jianzeng Dong.;Laurent Macle.;Changsheng Ma.
来源: Circulation. 2026年153卷5期297-306页
Observational studies have suggested that SGLT2 (sodium-glucose cotransporter 2) inhibitors are associated with a lower risk of atrial fibrillation (AF) recurrence after catheter ablation in patients with AF with concomitant diabetes, heart failure, or chronic kidney disease. However, no randomized trial to date has tested whether SGLT2 inhibitors reduce AF recurrence after ablation in patients without established indications. We therefore investigated the effect of dapagliflozin on prevention of early recurrence of AF after catheter ablation in patients without current indications for SGLT2 inhibitors.
12. Effect of Aficamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy in SEQUOIA-HCM.
作者: Xiaowen Wang.;Maria A Pabon.;Tracy T Makuvire.;Reziwanguli Maimaiti.;Theodore P Abraham.;Roberto Barriales-Villa.;Brian L Claggett.;Caroline J Coats.;Martin S Maron.;Ahmad Masri.;Benjamin Meder.;Michael E Nassif.;Iacopo Olivotto.;Anjali T Owens.;Sara Saberi.;Daniel L Jacoby.;Stephen B Heitner.;Stuart Kupfer.;Fady I Malik.;Amy Wohltman.;Scott D Solomon.;Sheila M Hegde.
来源: Circ Heart Fail. 2026年19卷1期e013918页
Women with obstructive hypertrophic cardiomyopathy often present with a greater burden of disease and worse prognosis. Whether there are sex-related differences in response to aficamten is unknown.
13. Randomized Comparison of Online Motivational Themes in Clinical Trial Recruitment.
作者: Tamunotonye Harry.;Zaib Hussain.;Jingyi Cao.;Ruth-Alma N Turkson-Ocran.;Stephen P Juraschek.;Erin D Michos.;Hailey N Miller.;Timothy P Lahey.;Timothy B Plante.;Yuanyuan Feng.
来源: Circ Cardiovasc Qual Outcomes. 2025年18卷12期e012945页
Targeted, digital recruitment strategies such as tailored websites using motivational themes may improve recruitment in clinical trials, but their effectiveness remains unclear. We hypothesized that themes emphasizing community well-being, personal health benefits, or access to perks would increase engagement and prescreening sign-ups compared with a standard contribution to science message in a clinical trial focused on Black adults.
14. Randomized Controlled Trial of Mechanical Thrombectomy With Anticoagulation Versus Anticoagulation Alone for Acute Intermediate-High Risk Pulmonary Embolism: Primary Outcomes From the STORM-PE Trial.
作者: Robert A Lookstein.;Stavros V Konstantinides.;Ido Weinberg.;Suhail Y Dohad.;Zachary Rosol.;Grzegorz Kopeć.;John M Moriarty.;Sahil A Parikh.;Andrew Holden.;Richard N Channick.;Braedon McDonald.;Khanjan H Nagarsheth.;Kei Yamada.;Rachel P Rosovsky.; .
来源: Circulation. 2026年153卷1期21-34页
Patients with intermediate-high risk pulmonary embolism (PE) have an elevated right ventricular (RV) to left ventricular (LV) diameter ratio and are at risk of early clinical decompensation and mortality. Reperfusion therapy aims to rapidly relieve acute RV pressure overload and to normalize hemodynamics. STORM-PE (A Prospective, Multicenter, Randomized Controlled Trial Evaluating Anticoagulation Alone Versus Anticoagulation Plus Mechanical Aspiration With the Indigo Aspiration System for the Treatment of Intermediate-High Risk Acute Pulmonary Embolism) is the first reported randomized controlled trial to test the efficacy and to evaluate the safety of mechanical thrombectomy, specifically computer-assisted vacuum thrombectomy (CAVT) with anticoagulation compared to anticoagulation alone.
15. Efficacy and Safety of Very Low Achieved LDL Cholesterol in Patients With Previous Ischemic Stroke.
作者: Victorien Monguillon.;Peter J Kelly.;Michelle L O'Donoghue.;Jeong-Gun Park.;Erin A Bohula.;Jeffrey L Saver.;Dan Atar.;Anthony C Keech.;Peter S Sever.;Huei Wang.;Gabriel Paiva da Silva Lima.;Marc S Sabatine.;Robert P Giugliano.
来源: Circulation. 2026年153卷2期86-93页
Patients with previous ischemic stroke are at high risk for recurrent stroke and other major adverse cardiovascular events. The benefits of achieving very low levels of low-density lipoprotein cholesterol (LDL-C) in such patients is unclear.
16. Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.
作者: Robin Myte.;Andrea Mattsson.;Matt Poole.;Dustin J Little.;Per Nyström.;Alasdair Henderson.;Brian L Claggett.;Samvel B Gasparyan.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2025年18卷12期e013496页
Patients with cardiovascular conditions like heart failure (HF) often exhibit significant heterogeneity of the risk of clinical events. In clinical trials, large risk heterogeneity can result in an underestimation of treatment effects derived from Cox proportional hazards models. This occurs due to selection bias when estimating the hazard ratio, stemming from a disproportionate reduction of event-free patients in the control group compared with an effective active group over time, ultimately reducing the statistical power. Therefore, it is important to explore alternative analysis methods for outcome trials that are robust with respect to risk heterogeneity.
17. The Role of the Collateral Circulation in Stable Angina: An Invasive Placebo-Controlled Study.
作者: Christopher A Rajkumar.;Michael J Foley.;Fiyyaz Ahmed-Jushuf.;Shayna Chotai.;Florentina A Simader.;Muhammad Mohsin.;Ahmed Salih.;Sashiananthan Ganesananthan.;Nina Bual.;Ricardo Petraco.;Sukhjinder S Nijjer.;Sayan Sen.;Joban Sehmi.;Neil Ruparelia.;Jason N Dungu.;Alamgir Kabir.;Kare Tang.;Reto Gamma.;John R Davies.;Tushar Kotecha.;Graham D Cole.;James P Howard.;Thomas R Keeble.;Gerald J Clesham.;Peter D O'Kane.;Frank E Harrell.;Darrel P Francis.;Matthew J Shun-Shin.;Rasha K Al-Lamee.
来源: Circulation. 2025年152卷22期1541-1551页
Little correlation exists between the burden of ischemia and severity of angina in patients with stable coronary artery disease. This placebo-controlled, n-of-1 study investigated the relationship between ischemia, the collateral circulation, and symptoms in stable coronary artery disease. Additionally, it explored the association between progressive collateral recruitment and ischemic preconditioning.
18. Bailout Intracranial Angioplasty or Stenting After Thrombectomy for Acute Large Vessel Occlusion: 1-Year Outcomes of ANGEL-REBOOT.
作者: Feng Gao.;Xu Tong.;Ming Wei.;Xiaoxi Yao.;Lei Li.;Yuesong Pan.;Baixue Jia.;Thanh N Nguyen.;Ming Yang.;Dapeng Sun.;Ganghua Feng.;Guangxiong Yuan.;Chenghua Xu.;Zhengzhou Yuan.;Yue Wan.;Jing Wang.;Ping Jing.;Xinguang Yang.;Zhilin Wu.;Wei Hu.;Yuanfei Jiang.;Chaobin Wang.;Changming Wen.;Jianjun Tang.;Xiang Luo.;Yingchun Wu.;Ruile Shen.;Tuanyuan Zheng.;Yaxuan Sun.;Mingze Chang.;Yan Liu.;Yang Haihua.;Di Li.;Bo Yin.;Weihua Jia.;Dongjun Wan.;Guodong Xu.;Zaiyu Guo.;Dianjing Sun.;Yang Wang.;Jixin Duan.;Liyu Wang.;Guoqing Wang.;Liping Wei.;Gaoting Ma.;Xiaochuan Huo.;Dapeng Mo.;Ning Ma.;Zeguang Ren.;Liping Liu.;Xingquan Zhao.;Yilong Wang.;Jens Fiehler.;Yongjun Wang.;Zhongrong Miao.; .
来源: Circulation. 2025年152卷20期1397-1407页
The long-term benefits of bailout intracranial angioplasty or stenting (BAOS) after thrombectomy in patients with acute large vessel occlusion remain unclear. This study compared BAOS with standard therapy in patients with large vessel occlusion with unsuccessful recanalization (expanded Thrombolysis In Cerebral Infarction score 0-2a) or >70% residual stenosis after thrombectomy.
19. Transcatheter Closure of Patent Foramen Ovale With a Novel Biodegradable Device: A Prospective, Multicenter, Randomized Controlled Clinical Trial.
作者: Fengwen Zhang.;Jie Dong.;Peijian Wei.;Weiyi Fang.;Hao Hu.;Xiangqing Kong.;Ming Bai.;Jiahua Pan.;Zhiling Luo.;Ping Zhang.;Baiming Qu.;Jinpeng Hu.;Yaoxing Lu.;Chuangshi Wang.;Shouzheng Wang.;Xiangbin Pan.
来源: Circulation. 2026年153卷2期71-81页
Novel biodegradable patent foramen ovale (PFO) closure devices offer a promising therapeutic option. The efficacy and safety of the novel biodegradable devices compared with nitinol devices have not yet been investigated in a randomized clinical trial.
20. Complete Revascularization in Older Patients With Myocardial Infarction With or Without Complex Nonculprit Lesions.
作者: Alberto Sarti.;Andrea Erriquez.;Beatrice Dal Passo.;Gianni Casella.;Vincenzo Guiducci.;Raul Moreno.;Javier Escaned.;Federico Marchini.;Marta Cocco.;Filippo Maria Verardi.;Stefano Clò.;Serena Caglioni.;Jacopo Farina.;Emanuele Barbato.;Giuseppe Vadalà.;Caterina Cavazza.;Alessandro Capecchi.;Francesco Gallo.;Gianluca Campo.;Simone Biscaglia.
来源: Circ Cardiovasc Interv. 2025年18卷11期e015902页
The FIRE trial (Functional Assessment in Elderly Myocardial Infarction Patients With Multivessel Disease) showed the superiority of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease. Whether this result applies equally to patients at higher risk of ischemic events due to nonculprit lesion complexity is unclear.
|